NextCell Pharma AB (65G) Price & Analysis

0 Followers

65G Stock Chart & Stats

€0.05

>-€0.01(-2.19%)

At close: Jan 08 4:00 PM EST

€0.05

>-€0.01(-2.19%)

Day’s Range― - ―

52-Week Range€0.05 - €0.17

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€11.64M

Enterprise Value€97.59M

Total Cash (Recent Filing)€21.09M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta0.13

Next Earnings

Oct 22, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.38

Shares Outstanding126,392,960

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.13

Price to Book (P/B)1.36

Price to Sales (P/S)8.24

P/FCF Ratio-2.09

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)0.15

Revenue Forecast (FY)€22.81M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetThe absence of reported debt reduces refinancing pressure and interest-related financial risk, giving NextCell greater flexibility during development cycles. A debt-free structure can also preserve access to future financing options, although it does not offset the company’s current cash-burn challenges.

Proprietary Cell-therapy PlatformA proprietary stem-cell platform gives NextCell a defined technology base across cell therapies, clinical development, and related services. If development activities progress successfully, this platform could support multiple applications and create opportunities beyond a single therapeutic program.

Revenue Growth Over TimeThe reported revenue growth indicates that NextCell has generated some commercial or development-related expansion despite remaining unprofitable. Continued top-line progress could improve operating leverage over time, provided growth becomes large enough to absorb the company’s substantial fixed and development costs.

Bears Say

Persistent Cash BurnSustained negative operating and free cash flow means the business is consuming cash rather than funding operations internally. This can require repeated capital raising or other financing, potentially limiting strategic flexibility and increasing dilution or funding pressure during ongoing clinical development.

Deeply Negative ProfitabilityLarge gross and net losses show that current revenue is not covering the cost base, and margins remain deeply negative. Without meaningful improvement in economics or scale, continued investment in the platform may extend losses and delay the point at which the business can generate self-sustaining earnings.

Shrinking Equity BaseThe substantial decline in equity reflects the cumulative effect of ongoing losses and cash consumption, weakening the capital cushion available to support development. Negative returns on equity further indicate that invested capital is not currently producing economic returns, increasing reliance on future funding.

65G FAQ

What was NextCell Pharma AB’s price range in the past 12 months?

NextCell Pharma AB lowest stock price was €0.05 and its highest was €0.17 in the past 12 months.

What is NextCell Pharma AB’s market cap?

NextCell Pharma AB’s market cap is €11.64M.

When is NextCell Pharma AB’s upcoming earnings report date?

NextCell Pharma AB’s upcoming earnings report date is Oct 22, 2026 which is in 17 days.

How were NextCell Pharma AB’s earnings last quarter?

NextCell Pharma AB released its earnings results on Aug 27, 2026. The company reported -€0.008 earnings per share for the quarter.

Is NextCell Pharma AB overvalued?

According to Wall Street analysts NextCell Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does NextCell Pharma AB pay dividends?

NextCell Pharma AB does not currently pay dividends.

What is NextCell Pharma AB’s EPS estimate?

NextCell Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does NextCell Pharma AB have?

NextCell Pharma AB has 126,392,960 shares outstanding.

What happened to NextCell Pharma AB’s price movement after its last earnings report?

NextCell Pharma AB reported an EPS of -€0.008 in its last earnings report. Following the earnings report the stock price went down -6.977%.

Which hedge fund is a major shareholder of NextCell Pharma AB?

Currently, no hedge funds are holding shares in DE:65G

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

NextCell Pharma AB

NextCell Pharma AB operates as a biopharmaceutical enterprise, dedicating its efforts to the groundbreaking research and advancement of novel stem cell-based therapies within Sweden. A significant development from the company is ProTrans, an investigational drug derived from stem cells, primarily formulated to address autoimmune and inflammatory ailments. Beyond therapeutic development, NextCell Pharma AB also offers Cellaviva, a specialized stem cell banking service that enables families to securely preserve stem cells sourced from umbilical cord blood and tissue. Established in 2014, the company maintains its corporate headquarters in Huddinge, Sweden.